Market Closed -
Nasdaq
04:00:00 2025-02-14 pm EST
5-day change
1st Jan Change
18.31 USD
+3.62%
-2.09%
-4.49%
Arvinas Shares Fall Amid Breast Cancer Drug Trial Update, CCO Departure
January 10, 2025 at 02:38 pm EST
Oppenheimer Adjusts Price Target on Arvinas to $45 From $40, Keeps Outperform Rating
Feb. 12
MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Amid Concerns Over New Tariffs, Powell Testimony
Feb. 11
MT
Arvinas, Inc., Q4 2024 Earnings Call, Feb 11, 2025
Feb. 11
Arvinas' Q4 Loss Narrows, Revenue Misses Analysts' Expectations
Feb. 11
MT
Earnings Flash (ARVN) Arvinas Posts Q4 Net Loss $-0.63 a Share, vs. FactSet Est of $-0.96 Loss
Feb. 11
MT
Earnings Flash (ARVN) ARVINAS INC. Posts Q4 Revenue $59.2M, vs. FactSet Est of $62M
Feb. 11
MT
Arvinas, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024
Feb. 11
CI
Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer
Jan. 22
CI
Arvinas Shares Fall Amid Breast Cancer Drug Trial Update, CCO Departure
Jan. 10
MT
Arvinas, Inc. Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant
Jan. 10
CI
Arvinas, Pfizer Present 'Encouraging' Preliminary Data for Prospective Breast Cancer Treatment
Dec. 10
MT
Arvinas and Pfizer to Present Data from Phase 2 Portion of the TACTIVE-U Clinical Trial
Dec. 10
CI
Arvinas and Pfizer Announces Initial Phase 1B Data from the Tactive-U Sub-Study of Vepdegestrant in Combination with Abemaciclib At 2024 San Antonio Breast Cancer Symposium
Dec. 10
CI
Arvinas, Inc. Along with Pfizer, Inc. Evaluate Enrollment and Blinded Event Rates in Ongoing VERITAC-2 Phase 3 Second-Line Clinical Trial of Vepdegestrant as Monotherapy in Patients with Metastatic Breast Cancer
Nov. 19
CI
UBS Adjusts Price Target on Arvinas to $74 From $82, Maintains Buy Rating
24-10-31
MT
Arvinas' Q3 Net Loss Narrows, Revenue Rises
24-10-30
MT
Arvinas, Inc., Q3 2024 Earnings Call, Oct 30, 2024
24-10-30
Earnings Flash (ARVN) ARVINAS Reports Q3 Revenue $102.4M
24-10-30
MT
Arvinas, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
24-10-30
CI
Oppenheimer Adjusts Arvinas Price Target to $50 From $70, Maintains Outperform Rating
24-07-31
MT
Arvinas' Q2 Net Loss Narrows as Revenue Rises; Names Andrew Saik CFO
24-07-30
MT
Earnings Flash (ARVN) ARVINAS Posts Q2 Revenue $76.5M
24-07-30
MT
Arvinas, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024
24-07-30
CI
Arvinas, Inc.(NasdaqGS:ARVN) dropped from Russell 3000E Value Index
24-06-30
CI
Arvinas, Inc.(NasdaqGS:ARVN) dropped from Russell 2000 Value Index
24-06-30
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
ARVN: Dynamic Chart
Arvinas, Inc. is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The Company uses its PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It has four investigational clinical-stage programs: vepdegestrant (ARV-471) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-766 and bavdegalutamide for the treatment of men with metastatic castration-resistant prostate cancer, and ARV-102 for the treatment of patients with neurodegenerative disorders. Its product candidate, ARV-393, is designed to target the B-cell lymphoma 6, or BCL6 protein.
More about the company
Last Close Price
18.31 USD
Average target price
60.70 USD
Spread / Average Target
+231.51%
Consensus
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1